Microbix Biosystems Inc.
341 Bering Avenue
Toronto
Ontario
M8Z 3A8
Canada
Tel: 416-234-1624
Fax: 416-234-1626
Website: http://www.microbix.com/
228 articles with Microbix Biosystems Inc.
-
Microbix Presenting at Muskoka Capital Conference
9/25/2019
Meetings with Growth-Oriented Investors, September 27-29, 2019
-
Microbix Quality Products Attain European Registration
9/5/2019
Four IVD Controls to Support Performance of Human Papilloma Virus Tests
-
Microbix Reports Results for Q3 Fiscal 2019
8/12/2019
Microbix Biosystems Inc. reports results for its third quarter and nine months of fiscal 2019, the three-month and nine-month periods ending June 30, 2019 ("Q3" & "YTD"), with record YTD sales, strong YTD sales growth, improving percentage gross margin, and progress on its strategic goals.
-
Microbix Provides Bioreactor Update
8/1/2019
Largest Customer Confirms Conversion Timetable & Provides Full-Scale Order
-
FedDev Ontario Supports New Microbix Facility in Mississauga
7/30/2019
Contribution of $2.75 Million to Scale-up, Meet Demand, and Create Highly-Skilled Jobs
-
Microbix Reports Results for Q2 Fiscal 2019
5/13/2019
Record Sales of $4.25 Million, Sales Growth of 42%, and Material Net Earnings
-
Microbix to Present at Bloom Burton Conference
4/26/2019
Healthcare Investor Conference in Toronto on April 30 & May 1
-
Microbix Announces Management Changes
4/18/2019
Ken Hughes Appointed COO, Kathryn Froh Retiring
-
Microbix Announces Annual Meeting Voting Results
3/28/2019
Microbix Biosystems Inc., an innovator of biological products and technologies, announces the voting results from the Annual Meeting of Shareholders which was held on March 27, 2019.
-
Microbix Announces Issuance of Stock Options - February 25, 2019
2/25/2019
Microbix Biosystems Inc., an innovator of biological products and technologies, announces the issuance of stock options under its shareholder-approved 2018 stock option plan, as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.
-
Microbix Reports Results for Q1 Fiscal 2019
2/12/2019
Microbix Biosystems Inc. reports results for its first quarter of fiscal 2019, the three-month period ending December 31, 2018 ("Q1"), with lower sales, improving percentage gross margin, improving and positive cash flow from operations and progress toward its operational goals.
-
Microbix Provides Quality Assessment Products Update
2/5/2019
New Customers, More Products, and Expanding Capacity
-
Microbix Enhances Quality Management System
12/24/2018
ISO 13485:2016 Medical Devices Certification Attained
-
Microbix Wins Business Award of Excellence
11/19/2018
Recognized with 2018 Business Innovation Award by MBOT
-
Microbix Exhibiting at MEDICA Trade Fair
11/6/2018
Showcasing Antigen and Quality Assessment Products
-
Microbix to Present at Muskoka Capital Conference
9/27/2018
Conference Introduces Growth Companies to Investor September 28-30, 2018
-
Microbix Reports Record Third Quarter Sales
8/14/2018
Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports financial results for its third quarter of fiscal 2018, the three-month period ending June 30, 2018 ("Q3"), with record sales and progress toward its operational goals.
-
Microbix Reports Record First Quarter Sales
2/14/2018
Total Q1 revenue was $2,885,567, an increase of 48% compared to the first quarter of fiscal 2017.
-
Microbix Expands Quality Assessment Product Family
1/18/2018
-
Microbix Reports Full Year and Fourth Quarter Results
12/21/2017
In 2017, the Company achieved a number of notable milestones, including attaining record sales of over $10 million.